Mårten Steen, MD, PhD, is a Managing Partner of HealthCap. He has extensive board experience from the life science sector including Ultragenyx, Ferrokin (acquired by Shire), Wilson Therapeutics (acquired by Alexion), Strongbridge (acquired by Xeris), Adcendo and Hemab.

Mårten earned an MD and PhD in Clinical Chemistry from Lund University, Sweden, and has previously worked with business development at Merck Serono and as a scientist focusing on coagulation disorders at Lund University and Novo Nordisk.